Genmab — Marts 2019
-
Netop Stockbull. Det er en
meget early case med langt mellem nyhederne. Min strategi er, at samle lidt frimærker op i disse nyhedssvage perioder. -
Akkurat på samme måde jeg startede i Genmab i tidernes morgen.
-
Casen er helt intakt. Du kan læse mere på hjemmesiden samt tilmelde dig nyhedsbrevet.
-
Nyhedsflowet siden børsnoteringen i 2015 kan ses her: https://alligatorbioscience.se/en/news/
-
-
God morgen.
-
on split dosis administration (only front page) https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1576871?scroll=top&needAccess=true
-
MAIA under the microscope — bringing trial design into focus - by our big friend Vincent Rajkumar https://www.nature.com/articles/s41571-019-0198-0?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+nrclinonc%2Frss%2Fcurrent+(Nature+Reviews+Clinical+Oncology+-+Issue)
-
Tak E L.
-
Hvad er rajkumars anke?
-
Et gæt på 2019 salgstal som rammer minimum guidance: http://www.proinvestor.com/?p=debat_1&postid=76753&thread=50&start=
-
@solsen...men særdeles højt profileret inden for MM...https://www.mayo.edu/research/faculty/rajkumar-s-vincent-m-d/bio-00085953
-
Nogen der har adgang til artiklen?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind